Interferon may assist with weight loss
AMARILLO, Texas Researchers at Amarillo Biosciences made a surprising discovery during tests of the autoimmune disease and fibromyalgia drug interferon, the company announced Wednesday.
In a study of 582 women, given one of five low doses of oral interferon or a placebo, a significant number of women given two of the doses experienced at least 5 percent weight loss. In response, Amarillo has filed a patent with the Patent and Trademark Office for the use of oral interferon to treat obesity.
Amarillo announced that it plans to conduct further studies. The Amarillo, Texas-based company is also researching the use of low-dose, oral interferon to treat chronic cough, influenza and opportunistic infections in people with HIV.
Florida e-prescribing organization releases registered vendor list
JACKSONVILLE, Fla. ePrescribe Florida, an organization that assists pharmacies in adopting electronic prescription systems, released a list of registered vendor solutions Tuesday.
Registered vendors made the list by meeting a set of e-prescribing and patient-safety criteria, such as alerting customers about potential interactions between drugs and allergies, as well as meeting Medicare electronic prescription standards. The list of 13 vendors includes H2H Solutions, iScribe, MedPlus, Misys Healthcare Systems and NextGen Healthcare.
ePrescribe Florida comprises various pharmacies, physicians, insurers, health-care improvement organizations and other organizations and professionals.
Cephalon sues Watson over Fentora patent
NEW YORK Drug maker Cephalon alleges that Watson infringed on its patent by developing a generic equivalent to its drug, Fentora.
Fentora (fentanyl citrate) is used to treat pain in cancer patients and received approval from the Food and Drug Administration in September 2006.
Watson applied for FDA approval of its generic version in April. In response, Cephalon filed a lawsuit in the U.S. District Court for the District of Delaware on June 2, asserting that Watson had infringed on patents ‘604 and ‘590, both of which expire in 11 years.
Fentora recorded sales of $135 million in 2007.
The FDA has, however, granted approval for Watson’s application for a generic version of KV Pharmaceutical’s Micro-K Extencaps in 600 mg and 750 mg doses.
The company that is now Wyeth sold global rights and the trademark for Micro-K to KV for $36 million in 1999. Micro-K had sales of $80 between March 2007 and March 2008, according to IMS Health data.